2016 American Transplant Congress
Kinetics of Cytomegalovirus Load in Kidney Transplant Recipients Receiving Everolimus or Mycophenolate Sodium and No Pharmacological Prophylaxis.
Hospital do Rim, São Paulo, Brazil.
The purpose of this analysis is to investigate the kinetics of cytomegalovirus (CMV) viral load in kidney transplant recipients receiving tacrolimus (TAC) plus everolimus (EVR)…2016 American Transplant Congress
Effect of Conversion to mTOR Inhibition on Allograft Fibrosis in Pediatric Liver Transplantation.
1Children's Mercy Hospital, Kansas City, MO; 2University of Kansas Medical Center, Kansas City, KS.
Background: Serial surveillance biopsies demonstrate post-transplant inflammation and fibrosis in long-surviving liver allografts. These findings can lead to cirrhosis and graft failure. We compared two…2016 American Transplant Congress
Conversion from Tacrolimus (TAC) to Sirolimus (SLR)-Based Immunosuppression in Pediatric Patients Who Underwent Liver Transplantation for Unresectable Hepatoblastoma – 2 Year Follow-Up.
Introduction: The appropriate use of Sirolimus (SRL) immunosuppression in pediatric liver transplantation has yet to be clearly defined. Even though Tacrolimus (TAC) is commonly used…2016 American Transplant Congress
The Incidence of Symptomatic Pericardial Effusion with Long-Term Sirolimus Therapy.
1Surgery, Albany Medical College, Albany, NY; 2Cardiology, Albany Medical College, Albany, NY.
BACKGROUNDSirolimus is an approved agent for immunosuppressive therapy after renal transplantation. Pericardial effusion and tamponade have been recognized as potentially serious complications of long-term sirolimus…2016 American Transplant Congress
Effects of Immunosuppression and Sun Exposure on Immune Cell Populations in Skin and Blood of Kidney Transplant Recipients.
BackgroundKidney transplant recipients (KTR) receiving sirolimus accrue fewer skin cancers than KTR receiving calcineurin inhibitor (CNI) based immunosuppression, potentially due to effects of sirolimus and…2016 American Transplant Congress
Sirolimus Regimen and Viral Serology as Risk Factors for Outcomes of Adult Kidney Transplants: 14-Year Cumulative Data in the United States.
Department of Medicine, Univ. of Florida, College of Medicine, Gainesville, FL.
BACKGROUND: The relative risks for patient mortality, graft loss and malignancy in the five years following kidney-only transplant (KT) based on sirolimus (SRL) regimen at…2016 American Transplant Congress
Modification of DC Phenotype and Function via Targeted Porous Silicon Nanoparticles.
Aims: Dendritic cells (DC) are the most potent antigen-presenting cell and are fundamental in the establishment of transplant tolerance. Targeting DC via the DC-SIGN receptor…2015 American Transplant Congress
Induction of a Costimulation-Susceptible Repertoire: A Case for Depletional Prior to Belatacept
1Surgery, Duke University, Durham, NC; 2Transplant Center, Emory University, Atlanta, GA.
Belatacept offers highly specific costimulation blockade to prevent recipient alloimmune responses with reduced toxicity. However, when applied with nondepletional induction therapy belatacept-based regimens have higher…2015 American Transplant Congress
Conditioning of Mesenchymal Stromal Cells With mTOR Inhibitor Enhances Regenerative Properties of Secretome and Attenuates Vascular Calcification
Similar to patients with chronic kidney disease, recipients of kidney transplants are a high-risk population for cardiovascular events due to arterial media calcification in particular…2015 American Transplant Congress
Comparison of Renal Outcomes for Liver Transplant Recipients With Pretransplant Renal Dysfunction Receiving Sirolimus Or Tacrolimus With Rabbit Antithymocyte Globulin Induction
Published data are limited describing renal outcomes in orthotopic liver transplant (OLT) recipients prescribed de novo sirolimus (SRL) maintenance immunosuppression and rabbit antithymocyte globulin (rATG).…
- « Previous Page
- 1
- …
- 3
- 4
- 5
- 6
- Next Page »